Search Results - "van Schaik, R."

Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy by Pratt, Victoria M, Cavallari, Larisa H, Del Tredici, Andria L, Gaedigk, Andrea, Hachad, Houda, Ji, Yuan, Kalman, Lisa V, Ly, Reynold C, Moyer, Ann M, Scott, Stuart A, van Schaik, R H N, Whirl-Carrillo, Michelle, Weck, Karen E

“…The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of…”
Get full text

A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype‐Based With Body‐Weight‐Based Tacrolimus Dosing After Living Donor Kidney Transplantation by Shuker, N., Bouamar, R., Schaik, R. H. N., Clahsen‐van Groningen, M. C., Damman, J., Baan, C. C., Wetering, J., Rowshani, A. T., Weimar, W., Gelder, T., Hesselink, D. A.

“…Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose to achieve therapeutic exposure compared with nonexpressers. This…”
Get full text

Pharmacogenetics: From Bench to Byte- An Update of Guidelines by Swen, JJ, Nijenhuis, M, Boer, A, Grandia, L, Maitland‐van der Zee, AH, Mulder, H, Rongen, GAPJM, Schaik, RHN, Schalekamp, T, Touw, DJ, Weide, J, Wilffert, B, Deneer, VHM, Guchelaar, H‐J

“…Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch…”
Get full text

A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients by Andrews, L. M., Hesselink, D. A., Schaik, R. H. N., Gelder, T., Fijter, J. W., Lloberas, N., Elens, L., Moes, D. J. A. R., Winter, B. C. M.

“…Aims The aims of this study were to describe the pharmacokinetics of tacrolimus immediately after kidney transplantation, and to develop a clinical tool for…”
Get full text

What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? – Considerations on pre-analytical aspects by the IFCC workgroup cfDNA by Danesi, R., Lo, Y.M.D., Oellerich, M., Beck, J., Galbiati, S., Re, M. Del, Lianidou, E., Neumaier, M., van Schaik, R.H.N.

“…•Preanalytical variables influence the quality and quantity of isolated cfDNA.•This paper compares preanalytical aspects published for cfDNA analysis.•Blood…”
Get full text

TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase by Pratt, Victoria M, Cavallari, Larisa H, Fulmer, Makenzie L, Gaedigk, Andrea, Hachad, Houda, Ji, Yuan, Kalman, Lisa V, Ly, Reynold C, Moyer, Ann M, Scott, Stuart A, van Schaik, R H N, Whirl-Carrillo, Michelle, Weck, Karen E

“…The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of…”
Get full text

Blood–brain barrier leakage may lead to progression of temporal lobe epilepsy by van Vliet, E. A., da Costa Araújo, S., Redeker, S., van Schaik, R., Aronica, E., Gorter, J. A.

“…Leakage of the blood–brain barrier (BBB) is associated with various neurological disorders, including temporal lobe epilepsy (TLE). However, it is not known…”
Get full text

Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662 by Diekstra, M H M, Klümpen, H J, Lolkema, M P J K, Yu, H, Kloth, J S L, Gelderblom, H, van Schaik, R H N, Gurney, H, Swen, J J, Huitema, A D R, Steeghs, N, Mathijssen, R H J

“…Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide polymorphisms (SNPs) in PK candidate genes have been associated…”
Get full text

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus by Becker, M L, Visser, L E, van Schaik, R H N, Hofman, A, Uitterlinden, A G, Stricker, B H C

“…The organic cation transporter 1, encoded by the SLC22A1 gene, is responsible for the uptake of the anti-hyperglycaemic drug, metformin, in the hepatocyte. We…”
Get full text

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations by Tang, J T, Andrews, L M, van Gelder, T, Shi, Y Y, van Schaik, R H N, Wang, L L, Hesselink, D A

“…Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and…”
Get more information

Exploring P-gp as moderator of side effects and effectiveness of risperidone in children and adolescents by Hermans, R.A., Gangapersad, R.N., Kloosterboer, S.M., van Schaik, R.H.N., Hillegers, M.H.J., Koch, B.C.P., de Winter, B.C.M., Dierckx, B.

Get full text

Pharmacogenetic Pathway Analysis of Docetaxel Elimination by Baker, SD, Verweij, J, Cusatis, GA, Schaik, RH, Marsh, S, Orwick, SJ, Franke, RM, Hu, S, Schuetz, EG, Lamba, V, Messersmith, WA, Wolff, AC, Carducci, MA, Sparreboom, A

“…The purpose of this study was to evaluate the affinity of docetaxel for 14 transporter proteins and assess the functional significance of 17 variants in five…”
Get full text

Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice by van Westrhenen, R, van Schaik, R H N, van Gelder, T, Birkenhager, T K, Bakker, P R, Houwink, E J F, Bet, P M, Hoogendijk, W J G, van Weelden-Hulshof, M J M

“…Effective pharmacologic treatments for psychiatric disorders are available, but their effect is limited due to patients' genetic heterogeneity and low…”
Get full text

Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe by de With, M., Sadlon, A., Cecchin, E., Haufroid, V., Thomas, F., Joerger, M., van Schaik, R.H.N., Mathijssen, R.H.J., Largiadèr, C.R.

“…The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European…”
Get full text

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study by Crona, D J, Ramirez, J, Qiao, W, de Graan, A-J, Ratain, M J, van Schaik, R H N, Mathijssen, R H J, Rosner, G L, Innocenti, F

“…The overall goal of this study was to provide evidence for the clinical validity of nine genetic variants in five genes previously associated with irinotecan…”
Get full text

Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β‐Blocker Users by Bijl, MJ, Visser, LE, Schaik, RHN, Kors, JA, Witteman, JCM, Hofman, A, Vulto, AG, Gelder, T, Stricker, BHCh

“…Several β‐blockers are metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). CYP2D6*4 is the main polymorphism leading to decreased enzyme…”
Get full text

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial by Dezentjé, V. O., van Schaik, R. H. N., Vletter-Bogaartz, J. M., van der Straaten, T., Wessels, J. A. M., Kranenbarg, E. M.-K., Berns, E. M., Seynaeve, C., Putter, H., van de Velde, C. J. H., Nortier, J. W. R., Gelderblom, H., Guchelaar, H.-J.

“…The clinical importance of CYP2D6 genotype as predictor of tamoxifen efficacy is still unclear. Recent genotyping studies on CYP2D6 using DNA derived from…”
Get full text

The CYP3A422 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients by de Jonge, H, Elens, L, de Loor, H, van Schaik, R H, Kuypers, D R J

“…Tacrolimus, a dual substrate of CYP3A4 and CYP3A5 has a narrow therapeutic index and is characterized by high between-subject variability in oral…”
Get full text

CYP2C92 allele increases risk for hypoglycemia in POR1/1 type 2 diabetic patients treated with sulfonylureas by Ragia, G, Tavridou, A, Elens, L, Van Schaik, R H N, Manolopoulos, V G

“…It is previously shown that carriers of the defective allele CYP2C9*3 that leads to impaired sulfonylurea metabolism are at increased sulfonylurea-induced…”
Get more information

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? by Danesi, R., Del Re, M., Ciccolini, J., Schellens, J.H.M., Schwab, M., van Schaik, R.H.N., van Kuilenburg, A.B.P.

Get full text